▲ Peaking
Business
Ipsen to Buy Kartos Therapeutics for Up to $1.75 Billion
Ipsen’s $1.75B Kartos deal reshapes blood cancer drug development—here’s what’s driving the bid
Jakafi
1 trends tracked about this subject — the full history, oldest to newest below.